M&A Deal Summary

Grifols Acquires Biotest

On September 17, 2021, Grifols acquired life science company Biotest for 1.6B EUR

Acquisition Highlights
  • This is Grifols’ 5th transaction in the Life Science sector.
  • This is Grifols’ largest (disclosed) transaction.
  • This is Grifols’ 1st transaction in Germany.

M&A Deal Summary
Date 2021-09-17
Target Biotest
Sector Life Science
Buyer(s) Grifols
Deal Type Add-on Acquisition
Deal Value 1.6B EUR

Target

Biotest

Dreieich, Germany
website
Biotest specializes in innovative hematology and clinical immunology solutions. The company develops, produces and markets biological medicinal products with applications in hematology, clinical immunology and intensive care. It's current portfolio includes 12 different products with a global commercial footprint in more than 90 countries. Biotest was founded in 1946 and is based in Dreieich, Germany.

Search 192,510 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Grifols

Barcelona, Spain

website

Category Company
Founded 1940
Sector Healthcare Services
Employees23,431
Revenue 6.1B EUR (2022)
DESCRIPTION

Grifols is a global healthcare company and biopharmaceutical manufacturer. Grifols was founded in 1940 and is based in Barcelona, Spain.

DEAL STATS #
Overall 8 of 8
Sector (Life Science) 5 of 5
Type (Add-on Acquisition) 3 of 3
Country (Germany) 1 of 1
Year (2021) 2 of 2
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-07 Kedrion - U.S. Plasma Donation Centers

Wilmington, Delaware, United States

Kedrion's U.S. Plasma Donation Centers provide plasma supply through organic and inorganic growth with immediate access to approximately 1.4 million liters per year and obtain approximately 240,000 liters per year.

Buy $55M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-14 VCN

Barcelona, Spain

VCN is a clinical-stage biotech company focused on developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV) and intravitreal (IVit) delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. VCN is based in Barcelona, Spain.

Sell $75M
Mergr

Product

Company

Legal